153 related articles for article (PubMed ID: 25960282)
21. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer.
Chappell NP; Teng PN; Hood BL; Wang G; Darcy KM; Hamilton CA; Maxwell GL; Conrads TP
J Proteome Res; 2012 Sep; 11(9):4605-14. PubMed ID: 22900918
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
23. Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines.
Ireland CM; Pittman SM; Jones SL; Harnett PR
Anticancer Res; 1994; 14(6B):2397-403. PubMed ID: 7872659
[TBL] [Abstract][Full Text] [Related]
24. The relationship between platinum drug resistance and epithelial-mesenchymal transition.
Brozovic A
Arch Toxicol; 2017 Feb; 91(2):605-619. PubMed ID: 28032148
[TBL] [Abstract][Full Text] [Related]
25. Acute application of cisplatin affects methylation status in neuroblastoma cells.
Tabata K; Sakai H; Nakajima R; Saya-Nishimura R; Motani K; Okano S; Shibata Y; Abiko Y; Suzuki T
Oncol Rep; 2011 Jun; 25(6):1655-60. PubMed ID: 21424131
[TBL] [Abstract][Full Text] [Related]
26. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells.
Procházka P; Libra A; Zemanová Z; Hřebačková J; Poljaková J; Hraběta J; Bunček M; Stiborová M; Eckschlager T
Cancer Sci; 2012 Feb; 103(2):334-41. PubMed ID: 22040216
[TBL] [Abstract][Full Text] [Related]
28. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
29. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
30. Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.
Boac BM; Xiong Y; Marchion DC; Abbasi F; Bush SH; Ramirez IJ; Khulpateea BR; Clair McClung E; Berry AL; Bou Zgheib N; Chon HS; Shahzad MM; Judson PL; Wenham RM; Apte SM; Berglund AE; Magliocco AM; Lancaster JM
Gynecol Oncol; 2016 Feb; 140(2):259-63. PubMed ID: 26731723
[TBL] [Abstract][Full Text] [Related]
31. RECK regulated endoplasmic reticulum stress response and enhanced cisplatin-induced cell death in neuroblastoma cells.
Chen Y; Tsai YH; Tseng SH
Surgery; 2013 Nov; 154(5):968-79. PubMed ID: 24084596
[TBL] [Abstract][Full Text] [Related]
32. Gene Expression Signature of Acquired Chemoresistance in Neuroblastoma Cells.
Jemaà M; Sime W; Abassi Y; Lasorsa VA; Bonne Køhler J; Michaelis M; Cinatl J; Capasso M; Massoumi R
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32948088
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
34. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
35. Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines.
Xu H; Choi SM; An CS; Min YD; Kim KC; Kim KJ; Choi CH
Biochem Biophys Res Commun; 2005 Mar; 328(2):618-22. PubMed ID: 15694393
[TBL] [Abstract][Full Text] [Related]
36. Synthetic lethal hubs associated with vincristine resistant neuroblastoma.
Fechete R; Barth S; Olender T; Munteanu A; Bernthaler A; Inger A; Perco P; Lukas A; Lancet D; Cinatl J; Michaelis M; Mayer B
Mol Biosyst; 2011 Jan; 7(1):200-14. PubMed ID: 21031175
[TBL] [Abstract][Full Text] [Related]
37. Candidate genes for cross-resistance against DNA-damaging drugs.
Wittig R; Nessling M; Will RD; Mollenhauer J; Salowsky R; Münstermann E; Schick M; Helmbach H; Gschwendt B; Korn B; Kioschis P; Lichter P; Schadendorf D; Poustka A
Cancer Res; 2002 Nov; 62(22):6698-705. PubMed ID: 12438269
[TBL] [Abstract][Full Text] [Related]
38. HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness.
Giannini G; Di Marcotullio L; Ristori E; Zani M; Crescenzi M; Scarpa S; Piaggio G; Vacca A; Peverali FA; Diana F; Screpanti I; Frati L; Gulino A
Cancer Res; 1999 May; 59(10):2484-92. PubMed ID: 10344762
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
40. Shotgun proteomics and network analysis of neuroblastoma cell lines treated with curcumin.
D'Aguanno S; D'Agnano I; De Canio M; Rossi C; Bernardini S; Federici G; Urbani A
Mol Biosyst; 2012 Apr; 8(4):1068-77. PubMed ID: 22315092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
